等待開盤 12-18 09:30:00 美东时间
-0.430
-0.21%
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
12-17 10:46
Morgan Stanley analyst Bob Huang downgrades Allstate (NYSE:ALL) from Overweight to Equal-Weight and lowers the price target from $245 to $215.
12-16 20:44
Allstate (ALL) declared $1.00/share quarterly dividend, in line with previous. Forward yield 1.89% Payable Jan. 2; for shareholders of record Dec. 1; ex-div Dec. 1. See ALL Dividend Scorecard, Yield C...
11-21 05:40
The Allstate Corporation (NYSE:ALL) today announced estimated catastrophe losses for the month of October of $83 million or $65 million, after-tax, from five wind and hail events.Allstate Protection policies in force are
11-20 21:12
今日重点评级关注:Piper Sandler:维持MeiraGTx Hldgs"超配"评级,目标价从28美元升至30美元;RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从26美元升至32美元
11-12 11:43
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
11-11 10:49
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22
BMO Capital analyst Michael Zaremski maintains Allstate (NYSE:ALL) with a Outperform and raises the price target from $235 to $244.
11-07 21:00